Cargando…

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives

PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cotta Ramusino, Matteo, Perini, Giulia, Altomare, Daniele, Barbarino, Paola, Weidner, Wendy, Salvini Porro, Gabriella, Barkhof, Frederik, Rabinovici, Gil D., van der Flier, Wiesje M., Frisoni, Giovanni B., Garibotto, Valentina, Teipel, Stefan, Boccardi, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175294/ https://www.ncbi.nlm.nih.gov/pubmed/33594474 http://dx.doi.org/10.1007/s00259-020-05187-x

Ejemplares similares

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Medial temporal lobe atrophy and posterior atrophy scales normative values
por: Cotta Ramusino, Matteo, et al.
Publicado: (2019)

Quantification of amyloid PET for future clinical use: a state-of-the-art review
por: Pemberton, Hugh G., et al.
Publicado: (2022)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Multitracer model for staging cortical amyloid deposition using PET imaging
por: Collij, Lyduine E., et al.
Publicado: (2020)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review
por: de Wilde, Arno, et al.
Publicado: (2018)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
por: Bommarito, Giulia, et al.
Publicado: (2022)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art
por: Cerami, Chiara, et al.
Publicado: (2022)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Longitudinal validity of PET‐based staging of regional amyloid deposition
por: Jelistratova, Irina, et al.
Publicado: (2020)

Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid
por: Heinen, Rutger, et al.
Publicado: (2020)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
por: Bader, Ilse, et al.
Publicado: (2023)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
por: Caprioglio, Camilla, et al.
Publicado: (2023)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
por: Shekari, Mahnaz, et al.
Publicado: (2023)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

PET amyloid in normal aging: direct comparison of visual and automatic processing methods
por: Haller, Sven, et al.
Publicado: (2020)

Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis
por: Bocancea, Diana I., et al.
Publicado: (2021)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Association of PET‐based stages of amyloid deposition with neuropathological markers of Aβ pathology
por: Teipel, Stefan J., et al.
Publicado: (2020)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vu227ooj37q502b1metmg0k6pl